Despite more than 200 clinical trials in Alzheimer disease (AD), there is no disease-modifying therapy for AD or for mild cognitive impairment (MCI). Actively or passively administered antibodies against amyloid β~1--42~ (Aβ~1--42~) have taken the lead in AD immunotherapy, but these approaches have so far encountered insurmountable difficulties caused by autoimmune manifestations and imaging abnormalities and have largely failed in clinical trials ([@B1]). We discovered the underlying immune defect of AD in phagocytosis of Aβ~1--42~ by macrophages in 2007 ([@B2]) and since then, have developed an immune approach with lipid mediators that regains functional Aβ~1--42~ phagocytosis ([@B3]). Innate immunity plays a bifunctional role in AD immunopathology: a negative role through IL-1-orchestrated inflammation ([@B4]) with activation of the membrane attack complex of complement C5b-9 ([@B5], [@B6]) and macrophage infiltration of the brain with disruption of the blood--brain barrier ([@B7]), and a positive role in uptake and clearance of Aβ~1--42~ by macrophages of healthy subjects ([@B2]). Aβ~1--42~ is the principal pathogenic molecule in the AD brain causing inflammation, neuronal apoptosis, disruption of neuronal connections, and congophilic angiopathy ([@B8]). Thus, appropriately regulating inflammation and increasing macrophage Aβ~1--42~ phagocytosis by ω-3 fatty acids (ω-3s) has a high therapeutic potential against MCI or subjective cognitive impairment (SCI).

The immunopathological mechanisms of failed Aβ~1--42~ clearance in patients with AD have not been reproduced in mouse models. In the mouse brain, Aβ~1--42~ clearance is attributable primarily to microglia ([@B9]). In the human brain, the macrophages have arguably a critical role in Aβ~1--42~ clearance, surmised from the defective macrophage phenotype of patients with AD ([@B2]) and disruption of the blood--brain barrier by apoptotic macrophages releasing Aβ~1--42~ into the vessel wall ([@B10]). In addition, the transcription of inflammatory genes in peripheral blood mononuclear cells (PBMCs) of patients with AD is deregulated either up or down in comparison to those in control subjects. Therefore, the increase of Aβ~1--42~ phagocytosis and modulation of inflammation by ω-3 docosahexaenoic acid (DHA), resolvin D1 (RvD1), and 1,25-dihydroxyvitamin D3 (1,25D3) ([@B11]) have therapeutic potential. The polyphenol resveratrol activates neuroprotective sirtuin-1 (Sirt1) and the genes for mitochondrial oxidative phosphorylation ([@B12]). Functioning macrophages could clear the AD brain, but patients have genetic heterogeneity in the apolipoprotein E (ApoE) gene and differences in macrophage responses. ApoE is a major lipid carrier in the brain. The ApoE ε4 allele is associated with late-onset AD through multiple mechanisms ([@B13]), including decreased Aβ~1--42~ clearance from the brain as observed in a mouse model ([@B14]), and functions as a transcription factor through binding to ∼1700 gene promoter regions associated with neuronal health ([@B15]). ApoE4 induces a proinflammatory state that is mediated, at least in part, by NF-κB, including a significant elevation of the proinflammatory cytokines IL6 and -8, which are associated with the pathologic changes found in AD ([@B16]). In addition, ApoE4 associates with soluble amyloid-precursor protein α (APPα) and reduces Sirt1 mRNA and protein expression ([@B16], [@B15]).

Brain-intrinsic mechanisms of DHA interacting with ApoE have been proposed in mouse models, including a change in the blood--brain barrier ([@B17]). However, these mechanisms do not address the immune defects of patients with MCI with specific changes in inflammatory activation, Aβ~1--42~ phagocytosis, and macrophage phenotype (see below). Health benefits of ω-3s have been extensively investigated and their effectiveness documented in rheumatoid arthritis ([@B18]). Epidemiologic studies of subjects at risk of dementia, with or without ω-3 intervention, have examined ω-3 blood levels and demonstrated that lower plasma concentrations of DHA are associated with cognitive decline ([@B17]). Seafood consumption correlates with lower AD neuropathology ([@B19]). In retrospective and some prospective intervention studies, ω-3s ([@B20], [@B21]) and vitamin D3 ([@B22]) had a positive effect on prevention of cognitive decline. The benefits of fish oil were stronger in non-ApoE ε4 subjects ([@B23]). In a randomized, placebo-controlled study, ω-3 supplementation reduced the rate of decline of the Mini--Mental State Examination (MMSE) score in comparison with a placebo, but the final MMSE score was below baseline ([@B24]). Thus, ω-3s, by themselves or as precursors of specialized proresolving mediators ([@B25]), appear appropriate for immunotherapy through brain-intrinsic and -extrinsic effects ([@B26]).

In this study, ω-3s were used in a combination with other active ingredients: antioxidants, vitamin D3, and resveratrol. This combination approach is in line with successful combination therapies for AIDS and tuberculosis, as well as with the metabolic enhancement of MCI therapy ([@B27], [@B28]). In a previous study, the Smartfish drink (Smartfish AS, Oslo, Norway) improved Aβ~1--42~ phagocytosis, normalized inflammation, and increased the anti-inflammatory mediator RvD1 ([@B3]). RvD1 is produced endogenously in macrophages from ω-3s ([@B29]) ([@B30]) and stimulates phagocytosis of Aβ~1--42~ ([@B11]). RvD1 signals through the GPCRs ALX and GPR32 ([@B31]), and Aβ~1--42~ phagocytosis enhancement by RvD1 is inhibited by a blockade of GPR32 ([@B11]). In addition, RvD1 promotes the proresolution phenotype of microglia *via* STAT-6 and PPAR-γ signaling ([@B32]).

We examined the effects of ω-3 supplementation on macrophage phenotype, phagocytosis, and MMSE in patients with subjective and objective defects in memory. Macrophage phenotype is involved in the outcome of many diseases, tissue homeostasis, and resolution or nonresolution of inflammation ([@B33]). The M1 status is associated with inflammatory conditions and is mitigated by ω-3s ([@B34]). Alternative activation of macrophages to M2 status has a bifunctional role in diseases, such as asthma ([@B35], [@B36]) and pancreatic fibrosis ([@B37]). We speculate that the outcome of immune therapy for patients with MCI depends in part on modulating inflammatory M1 (red zone) or anti-inflammatory M2 (white zone) macrophages at baseline to a proresolution and prophagocytic intermediate M1-M2 (green zone) phenotype.

Given the failures of previous monotherapeutic regimens and the advantages of combination therapies ([@B27]), we provided all but 1 patient with a drink containing ω-3s in combination with antioxidants, vitamin D3, and resveratrol. This drink has been used with success in controlled trials of behavioral problems ([@B38]) and obesity management. Nonetheless, in comparison to other disorders, the investigation of patients with MCI has been complicated by their baseline heterogeneity ([@B11], [@B39]), in part related to ApoE genotype. The patients selected for the study qualified as having MCI or SCI on admission, according to cognitive testing and shared the universal defect in Aβ~1--42~ phagocytosis. Imaging later showed specific diagnosis in 2 patients as Lewy body disease and vascular dementia. Our study has relevance to independently living patients with memory problems, irrespective of their pathology or brain imaging results.

MATERIALS AND METHODS {#s1}
=====================

Study design and population {#s2}
---------------------------

We performed an observational study by immune and cognitive tests of 18 independently living patients taking voluntary supplementation with the Smartfish ω-3 drink. Fifteen patients had the initial diagnosis of MCI by the criteria of Petersen *et al*. ([@B40]) and 3 patients the diagnosis of SCI, according to subjective complaints and subtle cognitive defects ([@B41]). Eleven patients (5 ApoE ε3/ε3 and 6 ApoE ε3/ε4) were followed by M1M2 testing in 90 visits. Cognition was tested by MMSE administered by the investigator. All subjects signed an informed consent approved by the University of California, Los Angeles Institutional Review Board.

ω-3 nutritional supplementation {#s3}
-------------------------------

The patients took voluntary daily supplementation with the ω-3 drink (Smartfish AS) \[a 200-ml emulsion containing 1000 mg DHA and 1000 mg eicosapentaenoic acid (EPA), both Pure arctic 360; Denomega, Oslo, Norway\] protected against oxidation through nano-sized, stabilized emulsion droplets; 5 g whey protein (Lacprodan DI-7017; Arla Foods; Aarhus, Denmark), 0.2 g lactose; 18 g carbohydrate from pomegranate and chokeberry juice; 10 μg vitamin D3 stabilized with tocopherol (DSM Nutritional Products, Basel, Switzerland); and 150 mg resveratrol (resVida, DSM). One patient had been taking a softgel ω-3 capsule (300 mg ω-3) per day (Nature's Bounty, Bohemia, NY, USA).

Isolation of PBMCs and macrophage cultures {#s4}
------------------------------------------

PBMCs were isolated from diluted heparin-anticoagulated blood by the Ficoll-Hypaque (Sigma-Aldrich, St. Louis, MO, USA) gradient method at 3000 rpm centrifugation for 20 min at room temperature. The mononuclear fraction was collected and washed 2 times with PBS, and the cells were resuspended with Iscove's modified Dulbecco's medium (IMDM). Macrophages were differentiated from 50,000 mononuclear cells by culture in IMDM with 10% autologous serum for 8--12 d in 8-well culture plates (Discovery Labware; BD Biosciences, Bedford, MA, USA).

Macrophage phenotyping {#s5}
----------------------

Macrophages in 8-well chambers were washed with PBS, fixed with 4% paraformaldehyde, permeabilized with 0.2% Triton X-100, and stained with antibodies against cluster of differentiation (CD)54 (intercellular adhesion molecule-1), CD80 (B7-1), CD163 (scavenger receptor), and CD206 (mannose receptor) (all from BioLegend, San Diego, CA, USA; 2.5 μg/ml in PBS containing 1% bovine serum albumin), followed by appropriate secondary Alexa 565 antibodies and phalloidin-FITC (Sigma-Aldrich). Other markers included arginase-1 for M2 macrophages, and NOS2, TNF-α, IL-1β, IL-6, and IL-12 for M1 macrophages. The preparations were examined with a BX60 microscope with a ×20 objective (Olympus, Melville, NY, USA). Three images were obtained in the order top, middle, and bottom of the dense macrophage growth in each well. The images were scanned with Image-Pro software (MediaCybernetics, Rockville, MD, USA). The M1-M2 type was calculated as the ratio of (CD54+CD80)/(CD163+CD206) in mean fluorescence intensity (MFI) units.

Modulation of macrophage type *in vitro* {#s6}
----------------------------------------

Macrophages were incubated for 18 h, with or without RvD1 or -3 (27 ng/ml; Cayman Chemicals, Ann Arbor, MI, USA) and were phenotyped with CD54, CD80, CD163, and CD206 before and after the treatment.

Flow cytometric fluorescent Aβ phagocytosis assay by monocytes {#s7}
--------------------------------------------------------------

PBMCs (0.5 × 10^6^) were suspended in IMDM with 10% autologous serum and were incubated with or without 2 µg/ml of fluorescent Aβ~1--42~, HiLyte Fluor 488 (Anaspec, Fremont, CA, USA) overnight at 37°C in a 5% CO~2~ incubator. The cells were washed 2 times with a fluorescence-activated cell sorting (FACS) buffer and then labeled for 30 min at 4°C with anti-CD14 PE (BD Biosciences). After incubation, the cells were washed 2 times with FACS buffer and fixed with 1% paraformaldehyde. Flow cytometry was performed on FACSCalibur (BD Biosciences). The data were analyzed with FlowJo software (Tree Star, Ashland, OR, USA) with a monocyte gating, based on forward and side scatter, and the results are expressed in MFI units.

Restriction isotyping of human ApoE {#s8}
-----------------------------------

ApoE genotyping to identify the ApoE alleles was performed as described elsewhere ([@B16]). The method involved using primer pairs to amplify the region set in the common sequence parts of ApoE isoforms. The amplified products were later digested with *Hha*I and subjected to electrophoresis on polyacrylamide gels. Each of the isoforms was distinguished by a unique combination of *Hha*I fragment sizes that enabled explicit typing of all homozygotic and heterozygotic combinations.

Statistical methods {#s9}
-------------------

For a given subject and outcome, the MMSE and MFI rates of change were computed as rate of change per year = 12\[(last value − first value)/*n* mo follow-up\] from first to last measurement. The M1/M2 ratio was coded 1 if the value was between 1 and 4 (in the green zone) and was coded 0 if below 1 or greater than 4 (outside of the green zone). The rates of change of these 0, 1 values were then computed for each subject as above. Rates of change were summarized with their medians. The *P* values for comparing continuous variables between groups including rates were computed with the nonparametric Kruskal-Wallis test, because the data did not follow normal distribution. The nonparametric Wilcoxon signed rank test was used to compute *P* values for comparing median rates to 0. Computations were performed with SAS 9.4 and JMP 12.0.1 (SAS, Inc., Cary, NC, USA).

RESULTS {#s10}
=======

Design of the study and overall results {#s11}
---------------------------------------

The study was an observation of patients with MCI on voluntary self-supplementation by ω-3s in the Smartfish drink. The patients were examined at each visit in 1--3 mo intervals by history and by testing macrophage type, level of Aβ~1--42~ phagocytosis, and MMSE score. The phenotype was scored according to the ratio of inflammatory over proresolution markers: (CD54+CD90)/(CD163+CD206). The M1M2 phenotype was considered to be noninflammatory (white zone) when the ratio was \<1.0; inflammatory M1 (red zone) when the ratio was \>4.0; and a proresolution M1-M2 (green zone associated with optimal Aβ~1--42~ phagocytosis) when the ratio was 1.0--4.0. The M1M2 results in the green zone were scored as 1 and in the white or red zone as 0. The results were analyzed according to the ApoE genotype ([**Fig. 1**](#F1){ref-type="fig"} and [**Table 1**](#T1){ref-type="table"}).

###### 

Immune and cognitive results in 5 patients with APO ε3/ε3 (*A*) and 6 with APO ε3/ε4 (*B*), according to the time after onset of ω-3 supplementation.
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###### 

Immune (M1-M2) and cognitive (MMSE) results in patients bearing ApoE ε3/ε3 and ApoE ε3/ε4 MCI and taking the ω-3-supplemented drink

                                                                    *P*        
  --------------------------- ------- --- ------- -------- -------- ---------- ----------
  M1/M2                                                                        
   Follow-up (mo)             ε3/ε3   5   6.0     5        15       0.5065     
                              ε3/ε4   5   5.0     0        18                  
   Green zone                                                                  
    Proportion                                                                 
     60%                      ε3/ε3   5   1.05    0.86     1.4                 0.1877
     70%                      ε3/ε4   5   1.97    0.26     4.0                 
    Rate of change (yr^−1^)   ε3/ε3   5   0.23    −0.27    2.6                 0.3750
                              ε3/ε4   5   −0.06   −2.06    0.0      *0.0820*   0.1250
  MFI, M1-M2                                                                   
   Follow-up (mo)             ε3/ε3   9   3       1        22       0.5915     
                              ε3/ε4   6   5       3        16                  
   Initial value              ε3/ε3   9   437     54.1     1,011    0.2875     
                              ε3/ε4   6   414     399      433                 
   Rate of change (yr^−1^)    ε3/ε3   9   1041    −2,064   10,308   0.4795     *0.0391*
                              ε3/ε4   6   2213    648      4,026               *0.0313*
  MMSE                                                                         
   Follow-up (mo)             ε3/ε3   9   11      1        29       0.7217     
                              ε3/ε4   9   6       1        25                  
   Initial value              ε3/ε3   9   26.0    24       30       0.4416     
                              ε3/ε4   9   26.0    20       30                  
   Rate of change (yr^−1^)    ε3/ε3   9   2.2     0.0      48.0     *0.0146*   *0.0156*
                              ε3/ε4   9   0.0     −20.0    12.0                0.4063

Significant differences within and between groups are in italics. Rate of change (yr^−1^) into the green zone (M1/M2 ratio = 1--4) based on the coding as 1 (M1/M2 ratio = 1--4) ϴ (M1/M2 ratio \<1 or \>4).

The purpose of the study was to demonstrate the effect of ω-3s on 3 main objectives: *1*) MMSE rate of change (data available in 9 patients with ApoE ε3/ε3 and 9 with ApoE ε3/ε4); *2*) green zone M1-M2 phenotype change (data available in 5 patients with ApoE ε3/ε3 and 6 with ApoE ε3/ε4); and *3*) correlation between MMSE and M1-M2 phenotype ([Table 1](#T1){ref-type="table"}). The overall results were as presented below.

### Objective 1 {#s20}

MMSE rate in the ApoE ε3/ε3 group (9 patients): median change by 0 points per year (*P* = 0.015 compared to 0); in the ApoE ε3/ε4 group (9 patients): median change by 0 points (*P* = 0.40 compared to 0); significant difference between groups (*P* = 0.014) ([Table 1](#T1){ref-type="table"}). In the ApoE ε3/ε3 group, 4 patients had cognitive improvement of 2 or more points, but in the ApoE ε3/ε4 group 4 patients showed severe cognitive loss at the last follow-up ([**Table 2**](#T2){ref-type="table"}).

###### 

Individual immune and cognitive results in patients taking the ω-3-supplmented drink

                                              M1/M2   MFI    MMSE                     
  ------------------ ------ --------- ------- ------- ------ -------- -------- ------ ------
  ApoE ε3/ε3                                                                          
   2                 81/M   MCI       27      1.06    0.70   54       1186     24     29
   4                 78/M   Pre-MCI   21      1.40    3.23   377      1768     30     30
   8                 66/F   MCI       16      0.91    1.97   437      1825     26     29
   10                54/F   MCI       19      0.86    2.88   679      1968     28     30
   17                53/F   MCI       8       1.05    3.67   1011     1101     28     30
   20                80/M   MCI       9                      298      1157     26     30
   21                70/M   MCI       4                      437      1339     26     26
   22                82/F   MCI       3                      22       736      28     29
  Mean               70               13.38   1.06    2.49   414.3    1385.0   27.0   29.1
  [sd]{.smallcaps}                            0.21    1.18   322.0    426.1    1.85   1.36
  ApoE ε3/ε4                                                                          
   3                 40/M   MCI       10      0.26    1.06   399      1466     24     21
   9                 79/M   MCI       19      3.99    4.44   414      1880     26     17
   12                76/M   MCI       17      1.76    3.41   1280.0   3267     29     30
   14                90/F   MCI       17      0.61    0.25   400.0    1726     25     23
   15                60/M   Pre-MCI   9       3.20    1.46   419.0    743      30     30
   16                81/M   MCI-AD    10      4.03    5.28   433.0    1775     20     14
   18                81/F   Pre-MCI   4       1.22    0.67                     30     30
   19                63/F   MCI       11      2.17           679      1616     26     30
   23                88/F   MCI       8                      414.0    1315.0   25     21
  Mean               74               11.9    2.15    2.37   554.8    1723.5   26.1   24.0
  [sd]{.smallcaps}                            1.46    1.99   307.4    718.0    3.22   6.24

M1-M2 phenotype was tested by immunofluorescence microscopy, MFI by flow cytometry, and cognition by MMSE testing.

### Objective 2 {#s21}

Median M1-M2 green zone rate change in the ApoE ε3/ε3 group was 0.226 per year (*P* = 0.375 compared to 0) and in the ApoE ε3/ε4 group median green zone change was −0.063 (*P* = 0.125 compared to 0); significant difference between groups, *P* = 0.082 ([Table 1](#T1){ref-type="table"}).

### Objective 3 {#s22}

Correlation between MMSE and macrophage M1M2 phenotype: Spearman correlation in the ApoE ε3/ε3 group = 0.200 (*P* = 0.747) and in the ApoE ε3/ε4 group, Spearman correlation = 0.771 (*P* = 0.072); Spearman correlation of all patients **=** 0.483 (*P* = 0.132).

On ω-3 supplementation ApoE ε3/ε3 macrophages polarize to the intermediate M1-M2 phenotype, whereas ApoE ε3/ε4 macrophages show irregular polarization {#s12}
------------------------------------------------------------------------------------------------------------------------------------------------------

At baseline, patients bearing ApoE ε3/ε3 had low M1/M2 ratio (median M1/M2 ratio = 1.06), whereas patients with ApoE ε3/ε4 had higher M1/M2 ratio (median M1/M2 ratio = 1.97) ([Tables 1](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}). Macrophages of patients bearing ApoE ε3/ε3 increased at the median M1-M2 rate of 0.226 U/yr (*P* = 0.375 compared to 0), and macrophages of patients with ApoE ε3/ε4 had negative M1-M2 polarization of −0.063 (*P* = 0.125 compared to 0). The significance of the M1-M2 rate change difference between the ApoE groups was (*P* = 0.082) ([Table 1](#T1){ref-type="table"}). The irregularities of patients with ApoE ε3/ε4 were related in part to intercurrent health problems and lack of ω-3 supplementation ([Fig. 1](#F1){ref-type="fig"}). In patients with ApoE ε3/ε4, the baseline M1M2 type was in the red zone in 3 patients and increased further (4.4, 5.7, 5.28) and in 1 patient was in the white zone type and decreased further (from 0.61 to 0.25). All of these 4 patients had poor cognitive outcome ([Table 2](#T2){ref-type="table"}).

An example of M1M2 polarization in the ApoE ε3/ε3 group ([Fig. *2A*](#F2){ref-type="fig"}) shows the M1/M2 ratio increasing from baseline 0.66 to 1.99 (this patient had a baseline NOS/arginase ratio of 0.39). An example is shown where the ratio increased from 3.9 to 5.27 ([Fig. 2*B*](#F2){ref-type="fig"}). A control age-matched subject had M2 type (ratio 0.22) macrophages ([Fig. 2*C*](#F2){ref-type="fig"}) with excellent Aβ~1--42~ phagocytosis. Macrophage phenotype was confirmed by additional nonclassic markers, with the inflammatory marker NOS and the proresolution marker arginase ([**Fig. 3**](#F3){ref-type="fig"}).

###### 

Macrophage type at baseline and after ω-3 supplementation. *A*) Polarization in patients with ApoE ε3/ε3 from baseline M2 to M1-M2 after ω-3 supplementation. *B*) Polarization in patients with ApoE ε3/ε4 from baseline M1 to greater M1 type after ω-3. *C*) Control subject M2 type at baseline (no ω-3 supplementation).
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![Classic and other markers of M2 macrophages (*A*) and M1-M2 macrophages (*B*).](fasebj201600677RRf3){#F3}

Increased Aβ~1--42~ phagocytosis on ω-3 supplementation {#s13}
-------------------------------------------------------

On ω-3 supplementation, Aβ~1--42~ phagocytosis increased in both groups ([Table 1](#T1){ref-type="table"}). In the ApoE ε3/ε3 group, MFI increased with a median rate of change of 1041 MFI U/yr (*P* = 0.03 within group); in the ApoE ε3/ε4 group, with a median rate of change of 2213 MFI units per year (*P* = 0.03 within group; 0.47 between groups) ([Table 1](#T1){ref-type="table"}).

Case histories of patients with ApoE ε3/ε3 {#s14}
------------------------------------------

### Patient 2 {#s23}

A 79-yr-old man with diabetes mellitus under good control at baseline in 2014 with a history of memory problems in 2013. His initial MMSE was 23 and his diagnosis was MCI. He was in the study for 30 mo except during short periods of travel. He had prostatitis in July 2014. His MMSE continued to fluctuate, with a maximum MMSE score of 29. He was an avid bicyclist throughout the study until 2016 when he had a hip fracture after falling off his bicycle. Three months after his fall and hospitalization without the ω-3 drink, his MMSE dropped from 29 to 22.

### Patient 4 {#s24}

A 77-yr-old active film producer had recurring diverticulitis and underwent a colectomy in March 2014. At baseline he complained of mental fog with poor memory for names and words, and forgetfulness of simple tasks. His MMSE was 30, and his diagnosis was SCI. He had been taking the drink for 27 mo, except during extensive periods of foreign travel. All his MMSE results were 30. His general condition improved after colectomy: his word memory improved, and he was active in his profession.

### Patient 8 {#s25}

A 66-yr-old woman born in Afghanistan who received a PhD in international relations and was active as an advisor on women's issues in Afghanistan. She developed problems with adding numbers in 2014. Her initial MMSE was 26, and her diagnosis was MCI. She took the drink for 22 mo with intermittent noncompliance because of her travels. Her MMSE improved from 26 to 30.

### Patient 10 {#s26}

A 63-yr-old woman developed problems with remote memory and word- and concept-finding. Her initial MMSE was 28, and her diagnosis was SCI. She took the drink for 21 mo and increased complex carbohydrates and fish in her diet. Her remote memory improved and she developed a successful landscaping business.

### Patient 17 {#s27}

A 54-yr-old woman with a strong family history of dementia developed problems with finding appropriate words and addition of numbers in March 2015. Her initial MMSE was 28, and her diagnosis was MCI. She had history of attention deficit hyperactivity disorder and Graves' hyperthyroidism. She took a commercial fish oil preparation (not the Smartfish drink) for 8 mo. Her SPECTscan (single photon emission computed tomography) showed low activity overall. Her final MMSE was 30, but she continued to have word-finding difficulty.

Case histories of patients with ApoE ε3/ε4 {#s15}
------------------------------------------

### Patient 9 {#s29}

An 80-yr-old man, a retired civil engineer, took the drink for 22 mo. Before starting the study, he had a 2 yr history of memory and orientation problems. His first MMSE score was 26, and his diagnosis was MCI. His lowest MMSE was 6 in December 2015 when he was severely depressed and without supplementation. His MMSE improved to 23 in January 2016, but then his MMSE declined to 8, despite supervised supplementation. He had an increased homocysteine level of 15.6 μM (normal, 10.4--11.4 μM), normal C-reactive protein, a low DHEA level of 97 ng/ml (normal, 180--1250 ng/ml) and low testosterone of 0.7 pg/mo (normal, 30--135 pg/ml). Recently, his sensorium fluctuated, visual hallucinations were noted by his caregiver, and the fluorodeoxyglucose (FDG)--positron emission tomography/computed tomography (PET/CT) scan was consistent with dementia with Lewy bodies. He stopped taking the drink.

### Patient 12 {#s31}

A 74-yr-old man, a retired attorney, had a 5 yr history of anxiety, poor sleep, poor memory, and word-finding difficulty. His MRI showed ventricular enlargement and temporal lobe atrophy; his FDG-PET showed reduced glucose utilization in the temporal lobes. His initial MMSE was 29, and his diagnosis was MCI. His lowest MMSE was 28 in August 2015 after having pneumonia in July 2015---final MMSE, 30. He took supplements for 20 mo. His homocysteine level was 16.4 μM (increased above normal) and DHEA was 1.56 ng/ml (below normal).

### Patient 14 {#s32}

An 88-yr-old woman misplaced objects and had poor short-term memory, with an initial MMSE of 25; her diagnosis was MCI. She had taken the supplementation for 6 mo and then broke her hip in February 2015 and had a prolonged hospitalization without ω-3 supplementation until August 2015. Four months after the hip surgery, her MMSE declined to 11. She was restarted on the drink under supervision, and 4 mo later her MMSE increased to 25 and has remained between 24 and 27. She had low DHEA, but pregnenolone, progesterone, thyroid panel, and cortisol were normal. Her FDG-PET/CT showed hypometabolism of the posterior cingulate and parietotemporal cortex consistent with mild dementia. She did not take any AD drugs.

### Patient 15 {#s33}

A 66-yr-old physician with MMSE 30 and depression at the start of study and took the supplemented drink. His initial MMSE was 30, and his diagnosis was SCI. His mood and office work improved while he took supplementation for 7 mo. He then failed to continue in the study for 6 mo, but returned complaining of failing recent memory, poor judgement, and depression. His MMSE remained at 30.

### Patient 16 {#s34}

An 81-yr-old man was in the study for 11 mo. His initial diagnosis was MCI. He was taking supplements for 5 mo but had minor strokes that were diagnosed as multi-infarct dementia. His MMSE became unmeasurable, and he developed behavioral problems and was removed from the study by the caregiver.

Polarization of macrophages by RvD1 *in vitro* {#s16}
----------------------------------------------

In patients bearing ApoE ε3/ε3, *in vitro* treatment of macrophages by RvD1 reduced the M1/M2 ratio from 2.3 to 1.61, whereas in patients with ApoE ε3/ε4, this treatment increased the M1/M2 ratio from 1.89 to 2.35 ([**Table 3**](#T3){ref-type="table"}). An example of *in vitro* polarization by RvD1 in a patient with ApoE ε3/ε3 from 1.61 to 0.46 is shown **(**[**Fig. 4*A***](#F4){ref-type="fig"}). An example of idiosyncratic M1 polarization by RvD1 is shown where the ratio increased from 1.28 to 4.07 in a patient with ApoE ε3/ε4 ([Fig. 4*B*](#F4){ref-type="fig"}).

###### 

*In vitro* modulation of macrophage type by RvD1

  Patient            Date         No stimulation   RvD1 stimulation
  ------------------ ------------ ---------------- ------------------
  ApoE ε3/ε3                                       
   2                 5/31/2015    4.83             4.84
   2                 12/30/2015   1.99             0.89
   2                 2/21/2016    0.66             0.25
   8                 9/16/2015    1.97             1.27
   10                5/31/2015    2.06             0.82
  Mean                            2.30             1.61
  [se]{.smallcaps}                0.68             0.82
  ApoE ε3/ε4                                       
  12                 9/30/2015    1.55             0.89
  12                 7/19/2016    1.31             2.58
  14                 5/31/2015    4.09             8.57
  14                 9/16/2015    1.76             1.66
  14                 12/31/2015   1.61             0.46
  14                 2/22/2016    0.25             0.67
  15                 9/17/2015    1.28             3.35
  15                 6/30/2016    5.71             3.45
  16                 9/17/2015    1.28             3.35
  18                 4/13/2016    0.67             0.30
  19                 4/13/2016    2.17             1.79
  19                 4/13/2016    1.07             1.19
  Mean                            1.90             2.36
  [se]{.smallcaps}                0.44             0.66

Data are the M1/M2 ratio, with and without RvD1 stimulation. Macrophage phenotype was determined by immunofluorescence staining of macrophage with antibodies to CD54, CD80, CD163, and CD206.

![*In vitro* modulation of macrophage type by RvD1 stimulation. *A*) Patient with ApoE ε3/ε3, with (*a*) and without (*b*) RvD1. *B*) Patient with ApoE ε3/ε4, with (*a*) and without (*b*) RvD1.](fasebj201600677RRf4){#F4}

DISCUSSION {#s17}
==========

Our observational study of patients with MCI examined the effects of ω-3, antioxidant, and resveratrol drink supplementation on innate immunity and cognitive status in relationship to the ApoE genotype. Clinically and statistically significant findings (but limited by the study design and low number of subjects) were: *1*) in patients with ApoE ε3/ε3, a small improvement of cognitive level: MMSE improved by 2.2 points, whereas patients with ApoE ε3/ε4 did not change; the change within the ApoE ε3/ε3 group and between the groups was significant (*P* = 0.01); *2*) M1M2 polarization of macrophages in patients with ApoE ε3/ε3 to an M1-M2 type of 0.226 compared to the ApoE ε3/ε4 group rate of −0.063 was nearly significant (*P* = 0.08); *3*) correlation between the M1M2 rate and MMSE neared significance in the ApoE ε3/ε4 group (Spearman coefficient = 0.771, *P* = 0.072). The baseline M1M2 type in the red or white zone was a poor prognostic sign for cognition. The outstanding clinical "pearls" include patient 14, who recovered from dementia (MMSE 11) to her previous functioning (MMSE between 23 and 27) and patient 2, with improved MMSE score after 27 mo (initial 24, final 29). These results are limited by the small sample size; lack of randomization design to ω-3s *vs*. a placebo; intermittent compliance with ω-3 supplementation due to travel by patients 2, 4, and 12; diagnostic heterogeneity at baseline: 3 patients with SCI in the ApoE ε3/ε3 group *vs*. 2 with SCI and 1 with MCI-AD in the ApoE ε3/ε4 group; and the definition of the green zone M1/M2 ratio as 1--4 based on the observed relation of optimal M1-M2 to optimal MFI.

Overall results suggest that ω-3, antioxidant, and resveratrol supplementation were associated with stabilization or improvement for as long as 3 yr in the cognition of patients bearing ApoE ε3/ε3. The progress of those with ApoE ε3/ε4 was interrupted by intercurrent conditions, lack of supplementation, or a new diagnosis (Lewy body disease and multi-infarct dementia). An example of intercurrent conditions (hip fracture and hospitalization off supplementation), which were repaired by renewal of supplementation, is patient 14, who had a positive dementia FDG scan and lapsed into the dementia stage after surgery, but recovered to her previous cognitive status after discharge from the hospital and renewal of ω-3 supplementation.

Most patients with ApoE ε3/ε3 had M2 type at baseline, whereas 4 with ApoE ε3/ε4 had either extreme M1 red zone or M2 white zone macrophages. In the patients with ApoE ε3/ε3, ω-3 supplementation was associated with an increased rate of macrophage polarization to the M1-M2 type. In patients with ApoE ε3/ε4, polarization was irregular and associated with more extreme M1 macrophage type and poor outcome. Supplementation with ω-3 was associated with a significant improvement of MMSE status in patients with ApoE ε3/ε3 whose rate was significantly greater than 0 and superior in comparison to patients with ApoE ε3/ε4 (*P* = 0.01). The inferior results in patients with ApoE ε3/ε4 may be related to the known negative effects of ApoE ε4, such as a gain of toxic function through Aβ~1--42~ aggregation and decreased clearance ([@B14]), inflammatory activation of macrophages ([@B42]), decreased lipid and glucose metabolism, and interference with neuronal signaling and mitochondrial function ([@B15]). As expected, *in vitro* stimulation by RvD1 decreased the M1/M2 ratio in patients with ApoE ε3/ε3, but this stimulation paradoxically increased the M1/M2 ratio in some patients with ApoE ε3/ε4. The results of ω-3s are limited to patients with MCI and SCI, as there were no cognitive benefits of ω-3 supplementation in patients with AD ([@B3]).

CONCLUSIONS {#s18}
===========

Supplementation with ω-3s/antioxidant/resveratrol provided in a drink with ω-3s and resveratrol is significantly (*P* = 0.01) associated with improved MMSE status and nonsignificantly (*P* = 0.08) associated with polarization of macrophages to an intermediate prophagocytic M1-M2 type in patients with ApoE ε3/ε3 in comparison to those with ApoE ε3/ε4. Supplementation with ω-3 brings into personalized clinical practice the immune benefits expected from ω-3 mediators called resolvins, and the results suggest a relationship between the improvements of innate immunity and cognition. Although the validity of this study is limited due to its small size and uncontrolled design, the results suggest a new immunologic approach to the widespread public health problem of dementia. The benefits of ω-3 supplementation should be clarified in larger controlled studies.
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1,25D3

:   1,25-dihydroxyvitamin D3

ω-3

:   ω-3 fatty acid

Aβ~1--42~

:   amyloid β~1--42~

AD

:   Alzheimer's disease

ApoE

:   apolipoprotein E

APP

:   amyloid-precursor protein

CD

:   cluster of differentiation

Cur

:   curcumin

DHA

:   docosahexaenoic acid

EPA

:   eicosapentaenoic acid

FACS

:   fluorescence-activated cell sorting

FDG

:   fluorodeoxyglucose

IMDM

:   Iscove\'s modified Dulbecco\'s medium

MCI

:   mild cognitive impairment

MFI

:   mean fluorescence intensity

MMSE

:   Mini--Mental State Examination

PET

:   positron emission tomography

PBMC

:   peripheral blood mononuclear cell

PPAR

:   peroxisome proliferator-activated receptor

Res

:   resveratrol

RvD

:   resolvin D

SCI

:   subjective cognitive impairment

SIRT

:   sirtuin

SPM

:   specialized proresolving mediator
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